Nakamuta, Makoto

Publishing since 1999 (Senior)

Has published 96 publications in 12 years

Number of publications published per year by Nakamuta, Makoto. (Source : PubMed)

Distribution of publications types for Nakamuta, Makoto. (Source : PubMed)
(a publication can be of different types, so total may exceed publications count)

Recent publications

•  Enjoji M, Nakamuta M. Is the control of dietary cholesterol intake sufficiently effective to ameliorate nonalcoholic fatty liver disease?  World J. Gastroenterol.  2010;16;7  
•  Enjoji M, Machida K, Kohjima M, Kato M, Kotoh K, Matsunaga K, Nakashima M, Nakamuta M. NPC1L1 inhibitor ezetimibe is a reliable therapeutic agent for non-obese patients with nonalcoholic fatty liver disease.  Lipids Health Dis  2010;9  
•  Enjoji M, Yada R, Fujino T, Yoshimoto T, Yada M, Harada N, Higuchi N, Kato M, Kohjima M, Taketomi A, Maehara Y, Nakashima M, Kotoh K, Nakamuta M. The state of cholesterol metabolism in the liver of patients with primary biliary cirrhosis: the role of MDR3 expression.  Hepatology international  2009  
•  Takemoto R, Nakamuta M, Aoyagi Y, Fujino T, Yasutake K, Koga K, Yoshimoto T, Miyahara T, Fukuizumi K, Wada Y, Takami Y, Saitsu H, Harada N, Nakashima M, Enjoji M. Validity of FibroScan values for predicting hepatic fibrosis stage in patients with chronic HCV infection.  J Dig Dis  2009;10;2  
•  Fujino T, Nakamuta M, Aoyagi Y, Fukuizumi K, Takemoto R, Yoshimoto T, Miyahara T, Harada N, Sakai H, Nakashima M, Enjoji M. Early decline of the HCV core antigen can predict SVR in patients with HCV treated by Pegylated interferon plus ribavirin combination therapy.  J Dig Dis  2009;10;1  
•  Yasutake K, Nakamuta M, Shima Y, Ohyama A, Masuda K, Haruta N, Fujino T, Aoyagi Y, Fukuizumi K, Yoshimoto T, Takemoto R, Miyahara T, Harada N, Hayata F, Nakashima M, Enjoji M. Nutritional investigation of non-obese patients with non-alcoholic fatty liver disease: the significance of dietary cholesterol.  Scand. J. Gastroenterol.  2009;44;4  
•  Furusyo N, Kajiwara E, Takahashi K, Nomura H, Tanabe Y, Masumoto A, Maruyama T, Nakamuta M, Enjoji M, Azuma K, Shimono J, Sakai H, Shimoda S, Hayashi J. Association between the treatment length and cumulative dose of pegylated interferon alpha-2b plus ribavirin and their effectiveness as a combination treatment for Japanese chronic hepatitis C patients: project of the Kyushu University Liver Disease Study Group.  J. Gastroenterol. Hepatol.  2008;23;7 Pt 1  
•  Yamashita N, Enjoji M, Kotoh K, Kato M, Ueda A, Horikawa Y, Tajiri H, Higuchi N, Kinukawa N, Nakamuta M, Takayanagi R. Investigation of hyperuricemia during pegylated-interferon-alpha2b plus ribavirin combination therapy in patients with chronic hepatitis C.  J Dig Dis  2008;9;1  
•  Kotoh K, Enjoji M, Kato M, Kohjima M, Nakamuta M, Takayanagi R. A new parameter using serum lactate dehydrogenase and alanine aminotransferase level is useful for predicting the prognosis of patients at an early stage of acute liver injury: a retrospective study.  Comp Hepatol  2008;7  
•  Higuchi N, Kato M, Shundo Y, Tajiri H, Tanaka M, Yamashita N, Kohjima M, Kotoh K, Nakamuta M, Takayanagi R, Enjoji M. Liver X receptor in cooperation with SREBP-1c is a major lipid synthesis regulator in nonalcoholic fatty liver disease.  Hepatol. Res.  2008;38;11  

[ See timeline ] [ See all publications ]